The Gadget My Family Reaches for Most Is the iPad 10, and It's $50 Off at Walmart
And right now, three colors of the 128GB 10th-gen iPad -- blue, silver and yellow -- are discounted by $50 at Walmart. That brings the price down to $299, which is a pretty sweet deal on a device that's become the hardest-working gadget in my home.
Since I've got kids, having a cheaper iPad on hand is a must. Apple's entry-level iPad gives us more than enough for basic game-playing, movie-watching, video chats and even some light work. Staying on the cheaper end of the iPad lineup also means that I'm in no rush to run out and grab the latest 11th-gen iPad, either. If the latest entry-level iPad received the same treatment the 2024 iPad Mini did, it might be a different story.
I can't justify the iPad as a true laptop replacement. However, on any trip my family goes on, it is the first device we decide to pack after a phone. It doesn't support the higher-end Pencil Pro stylus, but it can work for art with a USB-C Pencil just fine and has a lot of keyboard case options that nearly turn it into a laptop.
The iPad has fancier varieties that ramp up processing power, display quality and size, and add more storage. Still, in many ways, all iPads feel pretty much the same. That's the great success of the iPad in the first place, and it's also why cheaper iPads are still great gifts.
Hey, did you know? CNET Deals texts are free, easy and save you money.
The 10th-gen iPad is the perfect size and price
I like the 11-inch iPad size the most. It's a perfect blend of screen size and portability, and it's a great fit for keyboard cases. It's easy to slip into a bag and big enough to multitask with split-screen apps. I love doing quick writing and notetaking on iPads with keyboard cases, and the iPad is also my preferred quick and easy way to watch TV shows and movies by myself. I don't always play games on the iPad (I'm a game console person), but games like Catan, Balatro and Retro Bowl on the iPad are my personal obsessions.
Read more: Best iPad for 2025
I play with plenty of gadgets in my house, and the iPad is one of many tools in my tech collection. It really hits me how much the iPad is an essential family tool when I see how my wife and kids gravitate to it. It's comforting, instant, and most of the iPads in our home are years old, which doesn't even slightly affect how often we use them. That's why I suggest buying low is the way to go, despite how nice and speedy higher-end iPads can seem.
Why this deal matters
Discounts on Apple devices don't come around too often. So when a deal does become available, it's best not to wait, as it can disappear at any time. While this isn't the lowest price we've seen, this drops it down to the same price we saw during the major holiday sales.
In a world full of rapidly changing tech and gadgets, it's nice that each generation of the iPad can be so reliable and stable. Sure, the 10th-gen iPad might get updated next spring, but in the meantime it's the best affordable bet for basic uses, such as watching TV, creating art and playing select games.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Wire
24 minutes ago
- Geek Wire
Rivals team up: SpaceX sends 24 satellites into orbit for Amazon's Project Kuiper
A SpaceX Falcon 9 rocket sends Amazon's Project Kuiper satellites into space. (SpaceX / Amazon via LinkedIn) In a case of strange space bedfellows, SpaceX launched 24 satellites for Amazon's Project Kuiper constellation — which is competing with SpaceX's Starlink network to provide internet access from low Earth orbit. A SpaceX Falcon 9 rocket sent the satellites into space from Cape Canaveral Space Force Station in Florida at 2:30 a.m. ET Wednesday (11:30 p.m. PT Tuesday). This was the third launch of operational satellites for Project Kuiper, coming after two batches of 27 satellites each were delivered to orbit in April and June. Those earlier missions made use of United Launch Alliance's Atlas V rockets, but in order to meet its ambitious satellite deployment schedule, Amazon is turning to SpaceX for three Falcon 9 launches. SpaceX enjoys a significant edge over Amazon when it comes to providing satellite broadband access: Starlink has about 8,000 satellites in orbit and more than 6 million subscribers, while Project Kuiper is just getting off the ground. Project Kuiper's satellites are built at an Amazon facility in Kirkland, Wash., not far from the SpaceX complex in Redmond where Starlink satellites are manufactured. Earlier in the evening, a different Falcon 9 rocket lifted off from Vandenberg Space Force Base in California and sent another 26 Starlink satellites into orbit. Both of the Falcon 9 first-stage boosters successfully landed on their respective drone ships in the Pacific and the Atlantic, minutes after launch. About an hour after the Florida liftoff, SpaceX reported that all 24 of the Project Kuiper satellites for the KF-01 mission were successfully deployed — drawing a note of thanks from Panos Panay, Amazon's senior vice president of devices and services. 'Congrats to the amazing Amazon Project Kuiper team on another successful launch, and a big thanks to SpaceX for the ride to space,' Panay said in a LinkedIn post. 'Pumped to have another batch of Kuiper satellites heading into orbit!' Project Kuiper's mission operations center in Redmond took charge of the satellites to check on their health, raise their orbits and prepare for full commissioning. Amazon says it expects to begin delivering service to customers in late 2025. The company's license from the Federal Communications Commission calls for more than 1,600 satellites to be sent into orbit by mid-2026, with the full 3,232-satellite constellation due for deployment by 2029. Unless Amazon and its launch providers pick up the pace dramatically, the company might have to seek an extension.
Entrepreneur
24 minutes ago
- Entrepreneur
Zeus Hygia, Deep Algorithm Solutions, and Zulu Club Raise Early-Stage Funding
The below startups have announced their latest funding rounds. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Zeus Hygia Raises USD 2.5 Mn from NABVENTURES Zeus Hygia has secured USD 2.5 million in Series A funding from NABVENTURES, the venture capital arm of NABARD. The funding will support expansion in North America and Southeast Asia, advance research and development, and accelerate the creation of innovative nutraceutical ingredients targeting pain relief, weight control, women's health, and healthy aging. "The investment affirms our scientific foundation and mission to develop clinically supported natural ingredients," said Dr Arunkanth Krishnakumar, Co-founder and CEO of Zeus Hygia. Founded in 2018 by Dr Krishnakumar and Shankaranarayanan Jeyakodi, Zeus Hygia produces patented, evidence-based herbal extracts tailored for pharmaceutical, nutraceutical, and over-the-counter markets. The company operates on a business-to-business model and supplies high-efficacy plant-based ingredients to wellness companies across more than 15 countries. Its product line includes eight proprietary branded ingredients such as BioSOLVE Curcumin, Grantria, and Stadice, with several others under development. Zeus Hygia holds nine patents and supports its innovations through over 20 scientific publications. Its technology platforms enable the delivery of safe and natural active ingredients. Zeus Hygia has established a unit in the United States and is entering Southeast Asia through strategic partnerships. The company expects international markets to contribute nearly 70 percent of its revenue within three years, signaling strong global demand for its plant-derived solutions. Deep Algorithm Solutions Raises INR 10.8 Cr from Unicorn India Ventures Cybersecurity and AI startup Deep Algorithm Solutions has raised Rs 10.8 crore in a seed funding round led by Unicorn India Ventures. The funds will be used to expand engineering and threat intelligence teams, boost go-to-market efforts in India and Southeast Asia, and enhance integration with enterprise platforms such as Azure AD and Okta. The capital will also support the development of its behavioral AI and fraud analytics engine. "We are solving complex challenges in identity security and fraud prevention using indigenous AI. This investment affirms our belief in continuous authentication and behavioral intelligence," said JP Mishra, Founder and CEO. Founded in December 2021 by JP Mishra, Deep Algorithm Solutions specialises in cybersecurity for digital financial systems. The company's key offerings include adapIDAI, an adaptive behavioral identity engine, and BotShield, which mitigates zero-day attacks, DDoS threats, and application-level vulnerabilities. In the past year, Deep Algorithm has completed deployments at a private bank, a government agency, and a hospital. It has secured a government patent, filed for an international one, and is currently in talks with banks and fintech firms in India and abroad. With plans to expand into Mumbai, Bengaluru, Kenya, South Africa, and the UAE, the startup is also working on channel partnerships and preparing to launch a SaaS model for mid-sized enterprises. Zulu Club Raises USD 250K from TDV Partners Zulu Club has secured USD 250,000 in pre-seed funding from TDV Partners to expand its presence across Delhi NCR. The Gurgaon-based startup will deploy the capital to strengthen its logistics infrastructure, enhance personalisation features, and build deeper partnerships with local retailers. "We're building Zulu Club to reintroduce trust and experience into fashion shopping," said Adarsh Bhatia, founder of Zulu Club. "Consumers want speed, but not at the cost of confidence." Founded in 2024 by Adarsh Bhatia, Zulu Club offers a hyperlocal shopping experience that connects users to nearby malls and outlet stores via its app. The service allows customers to receive curated Try-at-Home kits with multiple items, try them on at their convenience, and pay only for what they keep. Zulu Club blends AI-powered curation with human-assisted personal shopping. Its flagship 100-minute delivery model targets millennial and Gen Z users who prioritize convenience and personalisation. The platform aims to reduce return rates and increase average order value by allowing consumers to try items before purchasing. The startup is currently operational in Gurugram and plans to expand across key neighborhoods in Delhi NCR. Its model addresses major challenges in online fashion such as low trust, poor fit, and high return rates, while also helping local retailers reach a broader customer base.
